Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023

2023/05/18 by Alexandra F. Dalton, Alpha Oumar Diallo, Anna N. Chard +95 · 4 citations
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · #Bacillus and Francisella bacterial research #Herpesvirus Infections and Treatments #Poxvirus research and outbreaks

paper · pdf · doi:10.15585/mmwr.mm7220a3

openalex publication_date 2023/05/18 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/01

Abstract

regardless of administration route or immunocompromise status.

Cited by

• Antigen-agnostic identification of poxvirus broadly neutralizing antibodies targeting OPG153
• Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection — New York, 2022
• The CDC Domestic Mpox Response — United States, 2022–2023
• Impact of interventions on mpox transmission during the 2022 outbreak in Canada: a mathematical modeling study of three different cities